Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
ANI Pharmaceuticals, Inc. (ANIP) filed a Form 144 notifying a proposed sale of 56,960 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $4,894,823.42. The form lists the approximate date of sale as 08/12/2025 and reports 21,688,772 shares outstanding for the issuer.
The securities to be sold were acquired as restricted stock from the issuer on four dates in 2025: 02/14 (12,333 shares), 02/28 (11,666), 03/07 (16,292), and 03/23 (16,669), which total the 56,960 shares listed for sale. The filing also states "Nothing to Report" for securities sold during the past three months and includes the standard signer representation that they do not possess undisclosed material adverse information. Certain filer identification and contact fields in the filing appear blank in the provided content.
ANI Pharmaceuticals (ANIP) has a Form 144 notice showing an insider proposes to sell 19,341 common shares, representing the full amount of two restricted stock grants received on 03/23/2022 (9,292 shares) and 04/27/2023 (10,049 shares). The planned sale is listed with an aggregate market value of $1,662,047.56 and an approximate sale date of 08/12/2025 on NASDAQ.
The shares to be sold compare with 21,699,636 shares outstanding, or roughly 0.09% of outstanding stock, and the filer reports no securities sold in the past three months. The filer also certifies they do not possess undisclosed material adverse information about the issuer.
ANI Pharmaceuticals (ANIP) filed a Form 144 notifying a proposed Rule 144 sale of 50,000 common shares to be handled by Morgan Stanley Smith Barney LLC on 08/12/2025 on the NASDAQ. The filing lists an aggregate market value of $4,303,590.00 and 21,699,636 shares outstanding, making the proposed sale roughly 0.23% of outstanding shares and implying an approximate price of $86.07 per share. The shares were reported as acquired the same day by stock option exercise from the issuer with cash payment. The filing reports no securities sold in the past three months. The extract does not include the filer identity or a dated signature in the provided content.
ANIP Q2-25 revenue jumped 53% YoY to $211.4 m, propelled by Cortrophin Gel (+66% to $81.6 m) and the first full quarter of ILUVIEN/YUTIQ sales ($22.3 m) acquired with Alimera. Generics grew 22% to $90.3 m.
Gross margin widened to 64.7% (58.2% LY) while SG&A climbed 55% on integration and commercial scale-up. Operating income rose to $13.9 m (6.6% margin) from $5.2 m; net income swung to $8.5 m, delivering diluted EPS of $0.36 versus a $0.14 loss. Six-month revenue is $408.5 m (+48%) with EPS of $1.05.
Cash reached $217.8 m as operating cash flow tripled to $110.8 m. Total debt remains high at $621.6 m (incl. $306.9 m converts), leaving net debt of ≈$404 m and leverage near 2.9× LTM sales. Intangible assets of $520 m and goodwill of $60.5 m reflect the Alimera deal; contingent consideration stands at $18.6 m.
Management stresses ongoing rare-disease momentum, manufacturing synergies and expanded market reach, but notes risks around debt covenants, rising rebate liabilities and Alimera integration.
ANI Pharmaceuticals, Inc. furnished an earnings press release covering its financial results for the second quarter ended June 30, 2025. The company disclosed that it issued this press release on August 8, 2025, and attached it as Exhibit 99.1 to the report. The information related to these results is being furnished rather than filed under securities laws, which means it is not automatically subject to certain liability provisions or incorporated into other regulatory filings unless specifically referenced.